Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Share-based Compensation (2018 - 2025)

Arcturus Therapeutics Holdings' Share-based Compensation history spans 8 years, with the latest figure at $6.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 24.11% year-over-year to $6.8 million; the TTM value through Dec 2025 reached $25.4 million, down 33.12%, while the annual FY2025 figure was $25.4 million, 33.12% down from the prior year.
  • Share-based Compensation reached $6.8 million in Q4 2025 per ARCT's latest filing, up from $5.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $10.1 million in Q1 2024 to a low of $5.7 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $7.9 million, with a median of $7.5 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: soared 722.97% in 2021, then tumbled 39.65% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $7.5 million in 2021, then fell by 13.14% to $6.5 million in 2022, then surged by 34.99% to $8.8 million in 2023, then rose by 1.91% to $9.0 million in 2024, then dropped by 24.11% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Share-based Compensation are $6.8 million (Q4 2025), $5.7 million (Q3 2025), and $6.2 million (Q2 2025).